<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zanamivir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zanamivir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zanamivir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10323" href="/d/html/10323.html" rel="external">see "Zanamivir: Drug information"</a> and <a class="drug drug_patient" data-topicid="11151" href="/d/html/11151.html" rel="external">see "Zanamivir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F235668"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Relenza Diskhaler</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868633"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Relenza Diskhaler</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1042836"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Neuraminidase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F235687"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 10 mg dose is provided by 2 inhalations (one 5 mg blister per inhalation):</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8cef53-c206-4ec0-8c9a-97d26dbfafc9">Influenza, seasonal, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, prophylaxis: Note:</b> Recommendations for patient selection for prophylaxis are variable (see guidelines for details); not recommended in patients with underlying respiratory disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral inhalation: Two inhalations (10 mg) once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of chemoprophylaxis varies with exposure or outbreak type, influenza vaccination status, presence of immunosuppression, and risk of severe complications from infection; in general, duration is as follows; see guidelines for additional details (AAP 2021; CDC 2021b; HHS [OI pediatric 2021]; IDSA [Uyeki 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">Household/nonoutbreak exposure: 7 days from last known exposure.</p>
<p style="text-indent:-2em;margin-left:8em;">Institutional outbreak: A minimum of 2 weeks and at least 1 week after the last identified case.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e42eebf-1cc9-4d9c-8452-1459db020923">Influenza, seasonal, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, treatment:</b>
<b>Note:</b> Therapy should begin within 2 days from onset of signs or symptoms. Not recommended for treatment of severe influenza, including in patients with disease severe enough to warrant hospitalization, due to lack of data (CDC 2021b). Not recommended in patients with underlying respiratory disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: Oral inhalation: Two inhalations (10 mg) twice daily for 5 days; doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193568"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary due to minimal absorption; however, has not been studied in severe renal insufficiency; the potential for drug accumulation should be considered.</p></div>
<div class="block dohp drugH1Div" id="F51193569"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F235672"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10323" href="/d/html/10323.html" rel="external">see "Zanamivir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8cef53-c206-4ec0-8c9a-97d26dbfafc9">Influenza, seasonal, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Postexposure prophylaxis (household exposure): <b>Oral inhalation:</b> Two inhalations (10 mg) once daily for 7 days after last known exposure (CDC 2020a).</p>
<p style="text-indent:-2em;margin-left:4em;">Postexposure prophylaxis (institutional outbreak): <b>Note:</b> Recommended for all residents regardless of vaccination status. Consider prophylaxis in employees, depending on vaccination status (CDC 2020a; IDSA [Uyeki 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral inhalation:</b> Two inhalations (10 mg) once daily; continue for ≥2 weeks and until ~7 days after identification of illness onset in the last patient (CDC 2020a; IDSA [Uyeki 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">Preexposure prophylaxis (community outbreak): <b>Note:</b> Consider use in patients at very high risk of developing complications from influenza infection (eg, severely immunocompromised patients) who are not protected by immunization (IDSA [Uyeki 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral inhalation:</b> Two inhalations (10 mg) once daily; continue until influenza activity in community subsides or immunity obtained from immunization (CDC 2020a; IDSA [Uyeki 2019]; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e42eebf-1cc9-4d9c-8452-1459db020923">Influenza, seasonal, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Therapy should begin within 48 hours from onset of signs or symptoms. Not recommended for treatment of severe or progressive influenza or patients with disease severe enough to warrant hospitalization, due to lack of data (CDC 2020a).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral inhalation:</b> Two inhalations (10 mg) twice daily for 5 days. Doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours (CDC 2020a).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed dose: </i>If a dose is missed, administer as soon as possible unless it is ≤2 hours before the next scheduled dose. Then, continue administration at the previous schedule; do not administer a double dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991273"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; however, the potential for drug accumulation should be considered.</p></div>
<div class="block doha drugH1Div" id="F50988560"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F235641"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Sore throat (or discomfort; prophylaxis, children: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (prophylaxis, children: 16%), nasal signs and symptoms (prophylaxis, children: 20%), tonsil disease (discomfort or pain; prophylaxis, children: 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (treatment, adolescents and adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (treatment, adolescents and adults: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (treatment, adolescents and adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤2%), rheumatism (prophylaxis: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (treatment, adolescents and adults: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, facial edema, hypersensitivity reaction (or hypersensitivity-like reaction), oropharyngeal edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior, agitation, anxiety, confusion, delirium, delusions, hallucination, impaired consciousness, nightmares, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea</p></div>
<div class="block coi drugH1Div" id="F235653"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to zanamivir or any component of the formulation (contains milk proteins)</p></div>
<div class="block war drugH1Div" id="F235638"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: Allergic-like reactions, including anaphylaxis, oropharyngeal edema, and serious skin rashes have been reported. Discontinue use and institute appropriate treatment if an allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including confusion, delirium, hallucinations, seizure, and/or self-injury) have been reported, primarily in pediatric patients; may be abrupt in onset. Direct causation is difficult to establish; influenza infection may also be associated with behavioral and neurologic changes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Bronchospasm, including serious cases and some with fatal outcomes, and decreased lung function have been reported in patients with and without airway disease; discontinue with bronchospasm or decreased lung function. For a patient with an underlying airway disease where a medical decision has been made to use zanamivir, a fast-acting bronchodilator should be made available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Not recommended for use in patients with underlying respiratory disease, such as asthma or COPD, due to lack of efficacy in influenza treatment and risk of serious bronchospasm. If zanamivir is prescribed in such patients, closely monitor respiratory function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nursing home patients: Effectiveness has not been established for prophylaxis of influenza in nursing home patients (per manufacturer); however, the CDC recommends zanamivir as an option to be used to control institutional outbreaks of influenza (refer to current guidelines) (CDC 2020a).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Powder for oral inhalation contains lactose; use contraindicated in patients allergic to milk proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Relenza inhalation powder should only be administered via inhalation using the provided Diskhaler delivery device. The commercially available formulation is a lactose containing powder and is <b>not</b> intended to be solubilized or administered via any nebulizer/mechanical ventilator; inappropriate administration has resulted in death.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Antiviral treatment should begin within 48 hours of symptom onset; however, the CDC recommends that treatment may still be beneficial and should be started in patients with severe, complicated or progressive illness, and in hospitalized patients if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza. Outpatients who are not at high risk for developing severe or complicated illness are not likely to benefit if treatment is started &gt;48 hours after symptom onset (CDC 2020a). Safety and efficacy have not been established in patients with significant underlying medical conditions. Not a substitute for annual flu vaccination; has not been shown to reduce risk of transmission of influenza to others. Patients must be instructed in the use of the delivery system. Consider primary or concomitant bacterial infections. Safety and efficacy of repeated courses have not been established.</p></div>
<div class="block foc drugH1Div" id="F235648"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relenza Diskhaler: 5 mg/actuation (20 ea) [contains lactose]</p></div>
<div class="block geq drugH1Div" id="F235634"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F2524730"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Relenza Diskhaler Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/ACT (per each): $3.54</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868634"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relenza Diskhaler: 5 mg/actuation (1 ea) [contains lactose]</p></div>
<div class="block admp drugH1Div" id="F52614028"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral Inhalation: Must be used with the provided breath-actuated Diskhaler delivery device. The foil blister disk containing zanamivir inhalation powder should not be manipulated, solubilized, or administered via a nebulizer. The foil blister disk (contains 4 x 5 mg doses) should be loaded into the Diskhaler; ensure that the silver foil is not broken and ensure the mouthpiece is clear prior to use. After loading the Rotadisk into the Diskhaler, activate to pierce blister; see product labeling for detailed instructions. Keep the Diskhaler in a level position and exhale fully prior to placing mouthpiece in mouth. Close lips around mouthpiece and inhale (steadily and deeply). Hold breath for a few seconds. Activate second blister to administer full dose (10 mg) and repeat steps. See product labeling for detailed instructions for loading, activating, and administering medication. Patients scheduled to use an inhaled bronchodilator at the same time as zanamivir should be advised to use their bronchodilator prior to zanamivir.</p></div>
<div class="block adm drugH1Div" id="F235650"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral inhalation: Must be used with Diskhaler delivery device. The foil blister disk containing zanamivir inhalation powder should not be manipulated, solubilized, or administered via a nebulizer. Patients scheduled to use an inhaled bronchodilator at the same time as zanamivir should use their bronchodilator prior to zanamivir. With the exception of the initial dose when used for treatment, administer at approximately the same time each day.</p></div>
<div class="block sts drugH1Div" id="F235665"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not puncture blister until taking a dose using the Diskhaler.</p></div>
<div class="block usep drugH1Div" id="F53569517"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis of influenza A or B infection (FDA approved in ages ≥5 years and adults); treatment of acute, uncomplicated influenza A or B infection in patients who have been symptomatic for ≤2 days (FDA approved in ages ≥7 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b> Zanamivir is not a substitute for annual influenza vaccination. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use zanamivir. Not recommended for treatment of severe influenza, including in patients with disease severe enough to warrant hospitalization, due to lack of data (CDC 2021b).</p></div>
<div class="block mst drugH1Div" id="F7731023"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Relenza may be confused with Albenza, Aplenzin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300233"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F235643"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F235656"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on multiple studies, the maternal use of zanamivir has not been shown to increase the risk of adverse pregnancy outcomes (CDC 2020a; CDC 2020b). However, pregnant and postpartum patients (≤2 weeks after delivery) have a higher risk for complications from influenza, including preterm delivery, pneumonia, admission to a hospital or ICU, and maternal and fetal death. Underlying maternal medical conditions increase these risks (ACOG 2018; CDC 2020a).</p>
<p style="text-indent:0em;margin-top:2em;">Zanamivir is not the preferred neuraminidase inhibitor for the treatment and prophylaxis of influenza during pregnancy, however it may be used as an alternative agent when otherwise appropriate (ACOG 2018; CDC 2020a; CDC 2020b); zanamivir may be preferred for prophylaxis use during pregnancy due to its limited systemic absorption (IDSA [Uyeki 2019]). Pregnant patients with known or suspected influenza can be treated with antiviral medications, regardless of trimester, vaccination status, or laboratory test results. Postexposure antiviral prophylaxis may be considered for pregnant and postpartum patients (including following pregnancy loss) (ACOG 2018; CDC 2020a; CDC 2020b).</p>
<p style="text-indent:0em;margin-top:2em;">An algorithm is available for the treatment of pregnant patients with known or suspected influenza (ACOG 2018). Refer to the Centers for Disease Control and Prevention recommendations for treatment updates based on resistance patterns (ACOG 2018; CDC 2020a).</p></div>
<div class="block mopp drugH1Div" id="F53569518"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory function; signs or symptoms of unusual behavior, including attempts at self-injury, confusion, and/or delirium; if used for prophylaxis, signs/symptoms of influenza infection.</p></div>
<div class="block pha drugH1Div" id="F235637"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Zanamivir inhibits influenza virus neuraminidase enzymes, potentially altering virus particle aggregation and release.</p></div>
<div class="block phk drugH1Div" id="F235652"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Inhalation: Systemic: ~4% to 17%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~16 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: &lt;10%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: None</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, serum: 2.5 to 5.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug); feces (unabsorbed drug)</p></div>
<div class="block phksp drugH1Div" id="F51192014"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Systemic exposure is increased after an IV dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F235658"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Relenza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Relenza Rotadisk</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34493538">
<a name="34493538"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2021-2022 . <i>Pediatrics</i>. Published online September 7, 2021. doi:10.1542/peds.2021-053745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/34493538/pubmed" id="34493538" target="_blank">34493538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247362">
<a name="30247362"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 753: Assessment and treatment of pregnant women with suspected or confirmed influenza. <i>Obstet Gynecol</i>. 2018;132(4):e169-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/30247362/pubmed" id="30247362" target="_blank">30247362</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Breastfeeding. Influenza (Flu). <a href="https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/influenza.html" target="_blank">https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/influenza.html</a>. Published January 12, 2021a. Accessed on January 19, 2021.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. Available at <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Last updated September 22, 2021b. Accessed October 8, 2021.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published November 30, 2020a. Accessed December 4, 2020.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention, (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. <a href="https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm" target="_blank">https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm</a>. Published November 30, 2020b. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11318072">
<a name="11318072"></a>Dreitlein WB, Maratos J, and Brocavich J. Zanamivir and Oseltamivir: Two New Options for the Treatment and Prevention of Influenza. <i>Clin Ther.</i> 2001;23(3):327-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/11318072/pubmed" id="11318072" target="_blank">11318072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21074132">
<a name="21074132"></a>Louie JK, Jamieson DJ, Rasmussen SA, et al. 2009 Pandemic Influenza A (H1N1) Virus Infection in Postpartum Women in California. <i>Am J Obstet Gynecol.</i> 2011;204(2):144.e1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/21074132/pubmed" id="21074132" target="_blank">21074132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Relenza (zanamivir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2021.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed May 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30834445">
<a name="30834445"></a>Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. <i>Clin Infect Dis</i>. 2019;68(6):895-902. doi:10.1093/cid/ciy874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zanamivir-pediatric-drug-information/abstract-text/30834445/pubmed" id="30834445" target="_blank">30834445</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13079 Version 142.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
